News
-
-
PRESS RELEASE
MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA
MIRA Pharmaceuticals, Inc. selects neuropathic pain as the primary indication for its novel oral ketamine analog, Ketamir-2, targeting neurologic disorders. Pre-IND meeting with FDA anticipated in Nov 2024 -
-
-
-
PRESS RELEASE
MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End
MIRA Pharmaceuticals, a leading pre-clinical-stage company, provides an update on its achievements and scientific advancements, nearing a milestone: IND application submission for Ketamir-2 and regulatory progress for MIRA-55 -
-
PRESS RELEASE
MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite: Nor-Ketamir - a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor
MIRA Pharmaceuticals unveils new preclinical data on innovative drug candidate Ketamir-2's metabolite Nor-Ketamir-2, showcasing enhanced bioavailability and formulation for advanced at-home neurological treatments -
-
PRESS RELEASE
MIRA Pharmaceuticals Announces Positive Discovery of Ketamir-2’s Selective NMDA Binding Mechanism of Action
MIRA Pharmaceuticals announced positive preclinical data for novel ketamine analog Ketamir-2, showing selective NMDA inhibition and enhanced safety profile, advancing towards potential IND submission
